Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
KxDL motif containing 1 (KXD1)
- Target
- KXD1
- Molecular classification
- Other (component of the BORC and BLOC-1 complexes, not a receptor, enzyme, transporter, or transcription factor)
01
Overview
KxDL motif containing 1 (KXD1) is a small, 20-kDa coiled-coil protein encoded by the KXD1 gene and is a component of the BORC (BLOC-1-related complex) and BLOC-1, essential for lysosomal positioning and biogenesis of lysosome-related organelles such as melanosomes and platelet dense granules. It physically interacts with BLOS1 and other BLOC-1 subunits, and its loss causes mild defects resembling Hermansky–Pudlak syndrome in model organisms. KXD1 is involved in vesicular trafficking, autophagy regulation, and may have disease associations in cancer and psychiatric disorders; however, it is not a known direct therapeutic target.
- Other names
- C19orf50BORCS4BLOC-1 related complex subunit 4FLJ25480MGC2749KXDLMST096MSTP096UPF0459 protein C19orf50KxDL motif-containing protein 1C10orf50
02
Mechanism of action
Not a direct therapeutic target; mechanism is via modulation of lysosomal function and trafficking. Altered KXD1 expression may impact responsiveness to nortriptyline, but there is no evidence of direct molecular targeting
03
Biological functions
Lysosome localizationIntracellular traffickingBiogenesis of lysosome-related organelles (such as melanosomes and platelet dense granules)Regulation of the BORC complex and lysosome movementRegulation of autophagic flux and lysosomal positioning
04
Disease associations
Hermansky–Pudlak syndrome (mimicked in knockout mouse models)Cancer (particularly non–small cell lung cancer prognosis marker)Neuropsychiatric phenotype and pigment cell biology (based on human and animal models)Host–pathogen interaction (implicated in tuberculosis pathogenesis and viral replication)
05
Safety considerations
No direct safety or therapeutic challenges reported; loss-of-function relates to mild cellular organelle defects rather than acute pathophysiology
06
Interacting drugs
Nortriptyline (altered expression of KXD1 has been linked to clinical response)
07
Biomarkers
Expression level of KXD1 (reported as a prognostic biomarker for non–small cell lung cancer and a potential predictive biomarker for response to nortriptyline)
Beyond the preview
Go deeper on KxDL motif containing 1 (KXD1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KxDL motif containing 1 (KXD1).